Jilin Aodong Pharmaceutical Group Co., Ltd. specializes in the manufacturing and marketing of pharmaceutical products. Besides, the group offers food products. Net sales break down by activity as follows: - sale of pharmaceutical products (89.4%); - sale of food products (6.8%); - other (3.8%). All sales are in China.

Employees

5,050

Sector

Pharmaceuticals

Calendar

10-23 Ex-dividend date - 0.2 CNY

More about the company

Quotes

Date	Price	Change	Volume
26-10-19	CN¥17.23	+0.76%	7,371,352
26-10-16	CN¥17.10	-0.29%	10,803,725
26-10-15	CN¥17.15	-1.72%	9,681,540
26-10-14	CN¥17.45	+0.29%	7,615,715
26-10-13	CN¥17.40	-0.57%	6,842,057

End-of-day quote Shenzhen S.E.

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Jilin Aodong Pharmaceutical Group Co., Ltd.

Company calendar

End-of-day quote Shenzhen S.E. 2026-10-19			5-day change	1st Jan Change
17.23 ^CNY	+0.76%		-1.71%	-11.78%

10-15	Jilin Aodong Pharmaceutical Group Co., Ltd. Announces Interim Profit Distribution Plan for 2026 to Be Implemented (A Shares), payable on October 23, 2026	CI
08-31	Jilin Aodong Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for the First Half of 2026	CI

Market Cap	20.2B 3.03B 2.7B 2.5B 2.27B 4.26B 287B 4.34B 29.96B 11.76B 150B 11.36B 11.12B 480B	P/E 2024	13.1x	P/E 2025	9.57x
Enterprise Value	19.48B 2.92B 2.6B 2.41B 2.19B 4.11B 277B 4.18B 28.89B 11.34B 144B 10.96B 10.72B 463B	EV / Sales 2024	7.76x	EV / Sales 2025	9.49x
Free-Float	66.63%	Yield 2024	2.9%	Yield 2025	2.56%

10-15	Jilin Aodong Pharmaceutical Group Co., Ltd. Announces Interim Profit Distribution Plan for 2026 to Be Implemented (A Shares), payable on October 23, 2026	CI
08-31	Jilin Aodong Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for the First Half of 2026	CI
08-28	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-09	China Approves Aodong Subsidiary's Levocarnitine Injection	MT
05-21	Jilin Aodong Pharmaceutical Gets China Approval for Supplemental Registration of Heart Drug	MT
05-12	Jilin Aodong Pharmaceutical Group Co., Ltd. Approves Final Cash Dividend on A Shares for the Year 2025, Payable on 08 July 2026	CI
04-29	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-20	Jilin Aodong Pharmaceutical's Attributable Profit Jumps 54% in 2025	MT
04-17	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-12	Aodong Pharmaceutical's Subsidiary Gets Nod to Market 10 Traditional Chinese Medicines	MT
01-26	Beijing Sun-Novo Pharmaceutical Research Co., Ltd. cancelled the acquisition of Jiangsu Langyan Life Technology Holdings Co., Ltd. from Li Qian, Ganzhou Langyi Investment Center (Limited Partnership) and Other shareholders.	CI
25-10-30	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-21	Aodong Pharmaceutical Gets China Supplementary Nod for Anti-Opioid Medication	MT

1 day	+0.76%
1 week	-1.71%
Current month	-1.03%
1 month	-1.88%
3 months	-4.60%
6 months	-5.38%
Current year	-11.78%

Jilin Aodong Pharmaceutical Group Co., Ltd. Stock

Stocks

000623

CNE000000719

Pharmaceuticals

Valuation: Jilin Aodong Pharmaceutical Group Co., Ltd.

Chart: Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest news: Jilin Aodong Pharmaceutical Group Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	17	17.56
1 month	17	17.91
Current year	16.36	20.93
1 year	16.36	22.08
3 years	12.49	22.08
5 years	12.49	22.08
10 years	12.49	29.43

Manager	Title	Age	Since
Shu Qin Guo CEO	Chief Executive Officer	63	2017-07-16
Kai Yang DFI	Director of Finance/CFO	49	2004-04-30
Shu Yuan Zhang DFI	Director of Finance/CFO	54	2007-06-17

Director	Title	Age	Since
Shu Qin Guo BRD	Director/Board Member	63	2000-01-31
Shu Yuan Zhang BRD	Director/Board Member	54	2020-07-16
Xiu Lin Li CHM	Chairman	74	2005-05-17

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/25/25	An Ning Li	Buy		100	0.0000%
7/29/24	Xiu Lin Li	Buy	Chairman	350,000	0.0302%
7/29/24	Shu Qin Guo	Buy	Chief Executive Officer	320,000	0.0276%

	2024	2025
Net sales	2.61B 391M 348M 323M 293M 551M 37.14B 561M 3.87B 1.52B 19.37B 1.47B 1.44B 62.02B	2.34B 350M 312M 289M 263M 493M 33.23B 502M 3.46B 1.36B 17.32B 1.31B 1.29B 55.48B
Net income	1.55B 233M 207M 192M 174M 328M 22.07B 333M 2.3B 903M 11.51B 873M 854M 36.86B	2.4B 359M 320M 296M 269M 506M 34.08B 514M 3.55B 1.39B 17.77B 1.35B 1.32B 56.91B
Net Debt	-386M -57.86M -51.5M -47.71M -43.39M -81.48M -5.49B -82.91M -572M -225M -2.86B -217M -212M -9.17B	-724M -109M -96.6M -89.49M -81.39M -153M -10.3B -156M -1.07B -422M -5.37B -407M -399M -17.2B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JILIN AODONG PHARMACEUTICAL GROUP CO., LTD.	+0.76%	-1.71%	-14.83%	+4.81%	3B
ELI LILLY AND COMPANY	-1.33%	+5.18%	+54.50%	+104.26%	1,120B
JOHNSON & JOHNSON	-0.69%	-2.93%	+31.35%	+66.17%	616B
ABBVIE INC.	-0.96%	+2.25%	+23.13%	+89.36%	504B
ROCHE HOLDING AG	+0.24%	+6.23%	+33.98%	+52.38%	367B
MERCK & CO., INC.	-1.59%	-1.35%	+69.39%	+40.83%	360B
NOVARTIS AG	-0.40%	+4.28%	+19.17%	+42.51%	288B
ASTRAZENECA PLC	-0.37%	+3.35%	-1.26%	+16.85%	258B
AMGEN INC.	-1.75%	+2.43%	+42.21%	+49.85%	234B
GILEAD SCIENCES, INC.	-2.00%	+1.26%	+24.64%	+92.13%	194B
Average	-0.13%	+2.88%	+28.23%	+55.91%	394.39B
Weighted average by Cap.	-0.47%	+3.51%	+37.86%	+71.67%